Form 4: AnaptysBio CFO Reports Equity Transactions and New Awards

AnaptysBio's Chief Financial Officer, Dennis Mulroy, reported the acquisition of new equity awards and a 'sell to cover' transaction for tax obligations.

Summary

• Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc. (ANAB), reported changes in his beneficial ownership of company securities.
• On January 6, 2026, Mulroy acquired 5,245 shares of Common Stock upon the settlement of Restricted Stock Units (RSUs).
• Also on January 6, 2026, Mulroy was granted 21,400 new Restricted Stock Units (RSUs) and 29,000 Stock Options with an exercise price of $43.91.
• On January 7, 2026, Mulroy sold 1,908 shares of Common Stock at a price of $45.11 per share.
• The sale of 1,908 shares was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations related to the vesting and settlement of RSUs, not a discretionary sale.
• Following these transactions, Mulroy beneficially owns 17,667 shares of Common Stock directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there was a sale of shares, it was non-discretionary for tax purposes. The significant grants of new RSUs and stock options indicate continued confidence in the executive and a long-term incentive structure, which is generally viewed favorably.

Positives

• The Chief Financial Officer received new grants of 21,400 Restricted Stock Units (RSUs) and 29,000 Stock Options, indicating continued long-term incentive and alignment with shareholder interests.
• The stock options have an exercise price of $43.91, providing potential upside if the company's stock price increases above this level.

Negatives

• The Chief Financial Officer sold 1,908 shares of Common Stock, reducing his direct beneficial ownership, although this was a non-discretionary 'sell to cover' transaction for tax purposes.

Future Outlook

The vesting schedules for the newly acquired Restricted Stock Units and Stock Options extend into future years (commencing January 6, 2027), contingent upon the Chief Financial Officer's continued provision of service to AnaptysBio, Inc. This indicates a long-term retention strategy for key management.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This filing reflects routine executive compensation practices within the biotechnology industry, where equity awards like Restricted Stock Units and stock options are commonly used to incentivize and retain key management personnel. 'Sell to cover' transactions are also standard practice for executives to manage tax liabilities arising from equity vesting.

Stakeholder Impact

• Shareholders: The grant of new equity awards aligns the CFO's interests with long-term shareholder value creation. The 'sell to cover' transaction is a minor, non-discretionary event with minimal impact.
• Employees: The equity compensation structure for the CFO reflects common practices for executive incentives and retention.

Next Steps

• The 21,400 Restricted Stock Units will vest as to 25% annually commencing on January 6, 2027, subject to continued service.
• The 29,000 Stock Options will vest as to 25% on January 6, 2027, and thereafter as to 1/48 of the total shares monthly until fully vested, subject to continued service.

Key Dates

Keywords

ANAB, AnaptysBio, Form 4, Insider Transaction, CFO, Restricted Stock Units, Stock Options, Equity Compensation, Sell to Cover